We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Dried Blood Spots Detect Clonal B-Cell Populations

By LabMedica International staff writers
Posted on 14 Oct 2013
Print article
Image: The automated MagNA Pure Compact instrument (Photo courtesy of Roche Applied Science).
Image: The automated MagNA Pure Compact instrument (Photo courtesy of Roche Applied Science).
The reliability of lymphoma diagnoses is strikingly different between developed and developing countries due to lack of access to advanced techniques.

Molecular methods are important tools for diagnosis and monitoring of many lymphoproliferative disorders, and new application of dried blood spots (DBS) for detecting clonal B-cell populations in peripheral blood (PB) has been proposed.

Scientists at the University of Padua (Italy) obtained blood samples from six patients with B-cell chronic lymphocytic leukemia (B-CLL) and five consenting healthy volunteer donors. Dried blood spot samples from African children with non-Hodgkin's lymphoma (NHL) were also analyzed.

Genomic DNA was isolated with the automated MagNA Pure Compact instrument (Roche Applied Science, Indianapolis, IN, USA) The extracted DNA samples were tested for B-cell immunoglobulin heavy chain (IGH) clonality with the IGH gene clonality assay (Invivoscribe Technologies; San Diego, CA, USA), containing BIOMED-2 primers, positive and negative controls.

The Namalwa B-cell line was used to establish that the assay was sensitive enough to detect 200 clonal cells in the analyzed sample. Very similar clonal results were obtained between DNA from DBS and fresh whole blood from patients with B-cell chronic lymphocytic leukemia. B-cell clonality can also be detected in DBS from African children with Epstein-Barr Virus (EBV)-associated diseases.

DBS cards are a feasible alternative for diagnosing and monitoring various diseases in the developing world. DBS sampling was also suitable to verify the presence of B-cell clonal populations circulating in the blood by immunoglobulin gene rearrangement analysis, with a view to offering molecular evaluation to the diagnosis and monitoring of lymphoproliferative diseases in resource-limited settings.

A diagnosis of leukemia is not usually problematic as immunophenotyping and cytogenetic analysis and histochemical staining can establish diagnosis in virtually all leukemia cases. However, a diagnosis of leukemia may sometimes be more complicated, and molecular clonality evaluation is thought to produce valuable additional information. DBS cards may be useful tools when the molecular analyses complementary to histomorphological/immunophenotypic evaluation are not available. The study was published in the October 2013 issue of the journal Leukemia Research.

Related Links:
University of Padua
Roche Applied Science
Invivoscribe Technologies


Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Multi-Function Pipetting Platform
apricot PP5
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.